1. Introduction {#sec1}
===============

Chronic hepatitis C impacts an estimated 70 million people worldwide \[[@B1]\]. The standard of care for treatment of the hepatitis C virus (HCV) is direct-acting antivirals (DAAs). Sustained virological response (SVR) is used as the primary efficacy endpoint for treatment, defined as HCV RNA levels below a designated threshold of quantification 24 weeks after the end of treatment (SVR24). More recently, SVR12 has been accepted as a valid efficacy endpoint because of its high rate of concordance with SVR24 \[[@B2]\]. Treatment with DAAs is associated with high rates of SVR along with minimal side effects \[[@B3]\].

During the previous era of interferon treatment for HCV, detectable viral load (VL) at end of treatment (EOT) negatively impacted the chance of achieving SVR \[[@B4], [@B5]\]. The significance of a low positive VL observed at EOT is unclear. We sought to determine the effect of EOT low positive VL with DAA therapies on SVR12 and SVR24. We hypothesized that most patients with low positive VL at EOT would still achieve SVR12 and SVR24.

2. Methods {#sec2}
==========

2.1. Patients and Study Design {#sec2.1}
------------------------------

This was a retrospective chart review of 1256 consecutive patients who had received DAA therapy from January 2014 to December 2018 at two large hepatology referral centers in the Dallas-Fort Worth area. Eligible HCV patients of all genotypes (1--6) that received recommended DAA therapies were included. Data collected included demographics, treatment regimen, and relevant lab values at start of treatment. Quantitative HCV RNA levels were checked four weeks into therapy, EOT, and four weeks, 12 weeks, and 24 weeks after treatment.

HCV RNA levels were measured using the Roche COBAS TaqMan HCV test. The assay has a lower limit of quantification (LLOQ), defined as the lowest HCV RNA concentration that can be accurately quantified, of 15 IU/mL. Any value below 15 IU/mL was determined to be unquantifiable. Treatment outcome for any patient with positive VL at EOT or beyond was noted.

3. Results {#sec3}
==========

Demographic, lab, and treatment characteristics of patients in the study are shown in [Table 1](#tab1){ref-type="table"}. Eight of the nine patients were Caucasian, and the majority were female. 1248 patients in the study had HCV RNA \< LLOQ at EOT and achieved SVR12.

Of the remaining eight patients who had low positive EOT VLs, all achieved SVR12 and SVR24. The EOT VL ranged from \<15 to 235 IU/mL. The highest VL observed was 235 IU/mL in a patient with genotype 2 treated with sofosbuvir and ribavirin for 12 weeks. The majority of patients were genotype 1a, and one patient had cirrhosis. The various DAA treatment regimens in EOT positive patients included sofosbuvir/ledipasvir for 12 weeks (*n* = 4), sofosbuvir/simeprevir for 12 weeks (*n* = 1), sofosbuvir/ribavirin for 12 weeks (*n* = 1), sofosbuvir/velpatasvir/voxilaprevir for 12 weeks (*n* = 1), and glecaprevir/pibrentasvir for 8 weeks (*n* = 1).

One patient that received sofosbuvir/ledipasvir had a negative EOT VL, but 23 IU/mL at week four after EOT also achieved SVR12 and SVR24.

4. Discussion {#sec4}
=============

This study evaluated the significance of EOT VL measurements in patients treated with various DAA regimens. When EOT VL is found to be positive, the question arises about extending treatment duration. The results of the study show that positive EOT VLs were not associated with treatment failure in patients treated with DAAs; hence, treatment duration need not be extended. The results also support the view that the utility of checking EOT VLs is low as all patients will likely achieve SVR.

Chronic hepatitis C infection develops with the loss of function of CD8 T-cells, known as T-cell exhaustion. Achieving SVR despite EOT positive VL can be explained by various hypotheses. The first is that DAA treatment leads to low levels of noninfectious virions unable to establish chronic infection, which are eventually cleared, leading to SVR \[[@B6], [@B7]\]. The second hypothesis argues that clearance of infected virions leads to a decline in T-cell exhaustion and simultaneous activation of cytotoxic T-cells that drive viral clearance \[[@B8]--[@B11]\]. The latter explanation is supported by research showing sustained and enhanced total T-cell immune response even after DAA therapy \[[@B12]\]. Third, it has been suggested that in patients who achieve SVR, viral suppression by DAAs results in an enhanced type I IFN response leading to higher activation of interferon-stimulated gene expression at EOT, resulting in elimination of residual virus \[[@B13]\]. Positive EOT VL may also be explained by laboratory contamination at the time the sample was analyzed.

The relationship between EOT low positive VL and SVR has been shown in a few studies. An analysis of patients treated with sofosbuvir and ledipasvir with HCV RNA above the LLOQ at EOT showed that all achieved SVR \[[@B14]\]. A retrospective study with 89 patients receiving sofosbuvir-based therapies showed that of the 6% of patients with EOT positive VL, all achieved SVR24 \[[@B15]\]. Another study of patients getting sofosbuvir-based therapy showed that rates of SVR12 among patients with undetectable EOT VL versus low-level viremia were similar \[[@B16]\]. The results from our study confirm the findings from the abovementioned studies and more importantly include data from newer DAAs (sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir).

Our results should be viewed in the context that we used the Roche COBAS TaqMan HCV assay, which has an LLOQ of 15 IU/mL. The more sensitive Abbot RealTime has an LLOQ of 12, which may lead to a higher frequency of residual HCV RNA detection, though clinical management would remain the same \[[@B17], [@B18]\].

A major strength of this study was the number of patients included, and the major limitation was its retrospective design.

5. Conclusion {#sec5}
=============

Low positive EOT VL does not negatively affect SVR12 and SVR24 in the DAA era, hence should not lead to extending treatment duration. We propose that EOT VL measurements should be avoided in most patients due to the limited clinical utility of the result.

Data Availability
=================

Data are available on request.
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###### 

Demographic, baseline lab, and treatment characteristics in EOT positive viral load patients.

  Patient   Gender   Race        Age   BMI (kg/m^2^)   INR   Albumin (g/dL)   Total bilirubin (mg/dL)   Platelet (x 1,000/mm^3^)   ALT (IU/L)   Baseline viral load (IU/mL)   Week 4 viral load (IU/mL)   EOT viral load (IU/mL)   Genotype   Fibrosis level (stage)   Treatment regimen   Previous treatment        SVR 12/24
  --------- -------- ----------- ----- --------------- ----- ---------------- ------------------------- -------------------------- ------------ ----------------------------- --------------------------- ------------------------ ---------- ------------------------ ------------------- ------------------------- -----------
  1         F        Caucasian   70    30              ---   3.6              1                         312                        53           3,715,090                     Neg                         62                       1a         2                        SOF + SIM           Peg-IFN + RBV             Y/Y
  2         F        Caucasian   62    27              1.1   4.4              0.6                       218                        77           3,895,292                     \<15                        235                      2b         ---                      SOF + RBV           ---                       Y/Y
  3         F        Caucasian   64    32              ---   3.9              0.31                      189                        27           3,200,000                     Neg                         26                       1b         0                        SOF + LED           ---                       Y/Y
  4         F        Black       71    27              ---   3.6              0.4                       357                        35           971,341                       Neg                         \<15                     1a         ---                      SOF + LED           ---                       Y/Y
  5^*∗*^    M        Caucasian   53    23              ---   4                0.5                       183                        39           2,108,530                     Neg                         Neg                      1a         ---                      SOF + LED           Peg-IFN + RBV             Y/Y
  6         M        Caucasian   29    29              ---   0.3              0.3                       340                        118          1,540,000                     120                         28                       1a         0                        SOF + LED           ---                       Y/Y
  7         M        Caucasian   68    30              1.2   1.1              1.1                       86                         73           3,001,000                     640                         62                       1a         4                        SOF + LED           ---                       Y/Y
  8         F        Caucasian   52    ---             1.1   1.1              1.1                       94                         82           2,300,000                     206                         18                       1a         4                        SOF + VEL + VOX     Peg-IFN + RBV SOF + LED   Y/Y
  9         F        Caucasian   62    ---             0.9   0.4              0.4                       239                        157          2,108,530                     128                         14                       1a         2                        GLE + PIB           ---                       Y/Y

^*∗*^Patients had a negative EOT viral load, but 23 IU/mL at week four after EOT. Abbreviations: SOF, sofosbuvir; SIM, simeprevir; peg-IFN, pegylated interferon; RBV, ribavirin; LED, ledipasvir; VEL, velpatasvir; VOX, voxilaprevir; GLE, glecaprevir; PIB, pibrentasavir.
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